

Nestlé India Limited

(CIN : L15202DL1959PLC003786)

Nestlé House

Jacaranda Marg

'M'Block, DLF City, Phase – II

Gurugram – 122002, Haryana

Phone: 0124 – 3940000

E-mail: investor@in.nestle.com

Website: www.nestle.in



PKR:SG:JK: 110:2024-25

31st January 2025

BSE Limited (BSE)

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai - 400 001

BSE Scrip Code: 500790

National Stock Exchange of India Limited (NSE)

Exchange Plaza, Plot No. C/1,

G Block, Bandra-Kurla Complex,

Bandra (East), Mumbai - 400 051

NSE Symbol: NESTLEIND

Subject: Integrated Filing (Financial) for the quarter and period ended 31st December 2024

Dear Madam/ Sir,

Pursuant to Securities and Exchange Board of India Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December 2024 read with relevant stock exchanges circulars, please find attached the Integrated Filing (Financial) for the quarter and period ended 31st December 2024. The same is being uploaded on the Company's website at www.nestle.in.

This is for your information and record.

Thanking you,

Yours truly,

NESTLÉ INDIA LIMITED

PRAMOD KUMAR RAI

COMPANY SECRETARY AND COMPLIANCE OFFICER

Encl.: *as above*

PART A - Financial Results



NESTLÉ INDIA LIMITED

Registered Office: 100 / 101, World Trade Centre, Barakhamba Lane, New Delhi – 110 001

Un-audited Standalone Financial Results for the Quarter and Nine months ended 31st December 2024

(₹ in million)

Three months ended			Particulars	Nine months ended		Previous financial year to date period ended	Financial year (fifteen months) ended
31.12.2024	30.09.2024	31.12.2023		31.12.2024	31.12.2023	31.12.2023	31.03.2024
(Un-audited)	(Un-audited)	(Un-audited)		(Un-audited)	(Un-audited)	(Un-audited)	(Audited)
45,660.5	48,831.4	44,217.9	A Income				
1,960.8	1,916.2	1,618.4	Domestic sales	140,576.9	136,662.8	182,790.1	233,006.2
47,621.3	50,747.6	45,836.3	Export sales	5,721.7	5,463.7	7,420.4	9,748.6
176.0	292.4	167.9	Sale of Products	146,298.6	142,126.5	190,210.5	242,754.8
47,797.3	51,040.0	46,004.2	Other operating revenue	678.2	831.2	1,052.5	1,184.1
44.4	68.6	303.0	i Revenue from Operations	146,976.8	142,957.7	191,263.0	243,938.9
			Other income	504.2	875.2	1,212.1	1,479.6
47,841.7	51,108.6	46,307.2	Total Income	147,481.0	143,832.9	192,475.1	245,418.5
20,758.2	20,252.4	19,775.1	B Expenses				
1,217.2	1,052.8	1,075.6	i Cost of materials consumed	60,442.8	58,723.0	80,549.5	102,168.8
(1,129.4)	834.0	(1,805.2)	ii Purchases of stock-in-trade	3,337.2	3,178.2	4,177.7	5,373.7
4,946.6	5,016.7	4,201.0	iii Changes in inventories of finished goods, work in progress and stock-in-trade	(406.4)	110.6	(400.1)	(456.8)
346.0	322.2	229.5	iv Employee benefits expense	15,017.3	13,949.3	18,491.8	23,360.6
1,325.1	1,216.0	1,086.9	v Finance costs (including interest cost on employee benefits plans)	985.0	822.8	1,192.9	1,454.9
10,811.5	11,996.3	11,469.0	vi Depreciation and amortisation	3,668.2	3,272.1	4,289.1	5,377.8
177.6	-	143.6	vii Other expenses	34,296.3	32,576.9	42,782.2	54,404.7
-	-	34.9	viii Impairment loss on property, plant and equipment	177.6	174.4	287.4	299.7
166.3	210.5	159.0	ix Net provision for contingencies	(120.0)	75.8	107.6	(7.5)
			x Corporate social responsibility expense	562.1	414.4	557.0	597.6
38,619.1	40,900.9	36,369.4	Total Expenses	117,960.1	113,297.5	152,035.1	192,573.5
9,222.6	10,207.7	9,937.8	C Profit Before Exceptional Items and Tax (A-B)	29,520.9	30,535.4	40,440.0	52,845.0
-	(2,908.2)	1,073.0	D Exceptional items [Charge / (Credit)]	(2,908.2)	57.1	57.1	(43.7)
9,222.6	13,115.9	8,864.8	E Profit Before Tax (C-D)	32,429.1	30,478.3	40,382.9	52,888.7
2,210.0	3,149.0	2,225.7	F Tax Expense:				
51.3	103.3	83.0	Current tax	7,953.0	7,411.8	9,997.0	13,156.8
			Deferred tax	185.2	446.2	399.2	403.5
6,961.3	9,863.6	6,556.1	G Profit for the Period (E-F)	24,290.9	22,620.3	29,986.7	39,328.4
			H Other Comprehensive Income				
(1,330.1)	-	326.4	a. (i) Items that will not be reclassified to profit or loss				
334.8	-	(82.2)	- Re-measurement of retirement defined benefits plans	(1,317.8)	265.0	(428.6)	(573.3)
			(ii) Income taxes relating to items that will not be reclassified to profit or loss	331.7	(66.8)	107.8	144.3
(19.4)	0.9	5.0	b. (i) Items that will be reclassified to profit or loss				
4.8	(0.2)	(1.2)	- Changes in fair value of cash flow hedges	(16.1)	(5.6)	3.4	(0.5)
			(ii) Income taxes relating to items that will be reclassified to profit or loss	4.0	1.2	(0.8)	0.1
(1,009.9)	0.7	248.0	Total Other Comprehensive Income (a+b)	(998.2)	193.8	(318.2)	(429.4)
5,951.4	9,864.3	6,804.1	I Total Comprehensive Income (G+H)	23,292.7	22,814.1	29,668.5	38,899.0
964.2	964.2	964.2	J Paid-up equity share capital (Face value – ₹1 Per share) *	964.2	964.2	964.2	964.2
44,890.6	38,939.2	29,963.3	K Other equity	44,890.6	29,963.3	29,963.3	32,444.7
7.22	10.23	6.80	L Earnings Per Share (EPS) (not annualized for quarters)				
			Basic / Diluted EPS (₹)	25.19	23.46	31.10	40.79
9,690.5	10,671.8	10,023.3	Additional information: Profit from operations [C - A(ii) + B(v) + B(x)]	30,563.8	30,897.4	40,977.8	53,417.9

* Effective from 5th January 2024, 1 (one) equity share having face value of ₹10.00 (Rupees Ten only) each, was sub-divided into 10 (ten) equity shares having face value of ₹1.00 (Rupee One only) each.

Notes:

1. Financial results have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Ind-AS and Schedule III (Division II) to the Companies Act, 2013.
2. The Company has made an investment for 49% stake in Dr. Reddy's and Nestlé Health Science Limited for development of nutraceutical business (refer Note 7 below). Pursuant to this, the investee entity has become an associate of the Company with effect from 24th July 2024. In compliance with section 129(3) of Companies Act, 2013 the financial results of the Company have been presented on standalone as well as consolidated basis.
3. For better understanding of the financial performance, the Company has chosen to present profit from operations as an additional information in the standalone statement of profit and loss. Profit from operations is derived from profit before exceptional items & tax less other income and adding back finance costs (including interest cost on employee benefits plans) and corporate social responsibility expense.
4. Comparisons are with reference to quarter ended 31st December 2023 unless otherwise specified :
 - a) Total sales and domestic sales for the quarter ended 31st December 2024 increased by 3.9% and 3.3% respectively.
 - b) Cost of materials consumed [B(i)+B(ii)+B(iii)] as a % to sales has increased from 41.6% to 43.8% for the quarter ended 31st December 2024.
5. Provision for contingencies are mainly for matters related to litigations/related disputes and other uncertainties requiring management judgement. Provision for contingencies/contingent liabilities are recognised/disclosed after a careful evaluation of the facts and legal aspects of the matters involved, in line with Ind AS 37 Provisions, Contingent Liabilities and Contingent Assets and Ind AS 12 Income Taxes.
6. The Board of Directors on 31st January 2025 have declared second interim dividend for the current financial year 2024-25 of ₹ 14.25 per equity share (Face value ₹ 1/- per equity share) amounting to ₹ 13,739.2 million, which will be paid on and from 27th February 2025 . This is in addition to the first interim dividend of ₹ 2.75 per equity share paid on 6th August 2024.
7. Exceptional items in the nine months ended 31st December 2024 comprise of gain on slump sale of the businesses mentioned below:
 - a) Nutraceutical Business ("NHSc") to Dr. Reddy's and Nestlé Health Science Limited.
 - b) Nestlé Business Services ("NBS") Division to Nestlé Business Services India Private Limited (Formerly known as Purina PetCare India Private Limited).
8. Based on the guiding principles given in Ind AS 108 Operating Segments, the Company's business activity falls within a single operating segment, namely Food. Accordingly, no separate segment information has been provided.
9. The previous financial year was for a period of fifteen months i.e., 1st January 2023 to 31st March 2024 due to transition to uniform financial year. Pursuant to this, the figures for comparative nine months period ended 31st December 2023 are the balancing figures between the published un-audited figures of the twelve month period ended 31st December 2023 and quarter ended 31st March 2023.

THE ABOVE RESULTS AND THIS RELEASE HAVE BEEN REVIEWED BY THE AUDIT COMMITTEE OF THE BOARD AT THEIR MEETING HELD ON 30th JANUARY 2025 AND APPROVED BY THE BOARD OF DIRECTORS AT THEIR MEETING HELD ON 31st JANUARY 2025.

For and on behalf of the Board

SURESH
NARAYANAN

Digitally signed by SURESH
NARAYANAN
Date: 2025.01.31 11:40:22
+05'30'

Suresh Narayanan
Chairman and Managing Director

Date: 31st January 2025

Place: Gurugram

Head Office: Nestlé House, Jacaranda Marg, M Block, DLF City Phase – II, Gurugram 122 002 (Haryana)

Registered Office: 100 / 101, World Trade Centre, Barakhamba Lane, New Delhi – 110 001

Corporate Identity Number: L15202DL1959PLC003786

Email ID: investor@in.nestle.com, Website: www.nestle.in

Phone: 011-23418891

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Nestle India Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Nestle India Limited (the "Company") for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement includes the results for the comparative nine months period ended December 31, 2023 (which are balancing figure between the published un-audited figures for the twelve months period ended December 31, 2023 and quarter ended March 31, 2023, on which we had issued separate limited review reports). Also refer note 9 to the accompanying statement of unaudited standalone financial results.

For S.R. BATLIBOI & Co. LLP

Chartered Accountants

ICAI Firm registration number: 301003E/E300005

**Pankaj
Chadha**Digitally signed by Pankaj Chadha
DN: cn=Pankaj Chadha, c=IN,
o=Personal,
email=pankaj.chadha@srb.in
Date: 2025.01.31 11:47:06
+05'30'

per Pankaj Chadha

Partner

Membership No.: 091813

UDIN: 25091813BMORCR7835

Place: Gurugram

Date: January 31, 2025



NESTLÉ INDIA LIMITED

Registered Office: 100 / 101, World Trade Centre, Barakhamba Lane, New Delhi – 110 001

Un-audited Consolidated Financial Results for the Quarter and Nine months ended 31st December 2024

(₹ in million)

Three months ended			Particulars	Nine months ended		Previous financial year to date period ended	Financial year (fifteen months) ended
31.12.2024	30.09.2024	31.12.2023		31.12.2024	31.12.2023	31.12.2023	31.03.2024
(Un-audited)	(Un-audited)	(Un-audited)		(Un-audited)	(Un-audited)	(Un-audited)	(Audited)
45,660.5	48,831.4	44,217.9	A Income				
1,960.8	1,916.2	1,618.4	Domestic sales	140,576.9	136,662.8	182,790.1	233,006.2
47,621.3	50,747.6	45,836.3	Export sales	5,721.7	5,463.7	7,420.4	9,748.6
176.0	292.4	167.9	Sale of Products	146,298.6	142,126.5	190,210.5	242,754.8
47,797.3	51,040.0	46,004.2	Other operating revenue	678.2	831.2	1,052.5	1,184.1
44.4	68.6	303.0	Revenue from Operations	146,976.8	142,957.7	191,263.0	243,938.9
47,841.7	51,108.6	46,307.2	i Other income	504.2	875.2	1,212.1	1,479.6
			ii Other income				
			Total Income	147,481.0	143,832.9	192,475.1	245,418.5
			B Expenses				
20,758.2	20,252.4	19,775.1	i Cost of materials consumed	60,442.8	58,723.0	80,549.5	102,168.8
1,217.2	1,052.8	1,075.6	ii Purchases of stock-in-trade	3,337.2	3,178.2	4,177.7	5,373.7
(1,129.4)	834.0	(1,805.2)	iii Changes in inventories of finished goods, work in progress and stock-in-trade	(406.4)	110.6	(400.1)	(456.8)
4,946.6	5,016.7	4,201.0	iv Employee benefits expense	15,017.3	13,949.3	18,491.8	23,360.6
346.0	322.2	229.5	v Finance costs (including interest cost on employee benefits plans)	985.0	822.8	1,192.9	1,454.9
1,325.1	1,216.0	1,086.9	vi Depreciation and amortisation	3,668.2	3,272.1	4,289.1	5,377.8
10,811.5	11,996.3	11,469.0	vii Other expenses	34,296.3	32,576.9	42,782.2	54,404.7
177.6	-	143.6	viii Impairment loss on property, plant and equipment	177.6	174.4	287.4	299.7
-	-	34.9	ix Net provision for contingencies	(120.0)	75.8	107.6	(7.5)
166.3	210.5	159.0	x Corporate social responsibility expense	562.1	414.4	557.0	597.6
38,619.1	40,900.9	36,369.4	Total Expenses	117,960.1	113,297.5	152,035.1	192,573.5
9,222.6	10,207.7	9,937.8	C Profit Before Share of (Profit)/Loss of an Associate, Exceptional Items and Tax (A-B)	29,520.9	30,535.4	40,440.0	52,845.0
78.1	37.2	-	D Share of (profit) / loss of Associate, net of tax	115.3	-	-	-
9,144.5	10,170.5	9,937.8	E Profit Before Exceptional Items and Tax (C-D)	29,405.6	30,535.4	40,440.0	52,845.0
-	(1,833.9)	1,073.0	F Exceptional items [Charge / (Credit)]	(1,833.9)	57.1	57.1	(43.7)
9,144.5	12,004.4	8,864.8	G Profit Before Tax (E-F)	31,239.5	30,478.3	40,382.9	52,888.7
			H Tax Expense:				
2,210.0	3,149.0	2,225.7	Current tax	7,953.0	7,411.8	9,997.0	13,156.8
54.4	(139.5)	83.0	Deferred tax	(54.5)	446.2	399.2	403.5
6,880.1	8,994.9	6,556.1	I Profit for the Period (G-H)	23,341.0	22,620.3	29,986.7	39,328.4
			J Other Comprehensive Income				
(1,330.1)	-	326.4	a. (i) Items that will not be reclassified to profit or loss				
334.8	-	(82.2)	- Re-measurement of retiral defined benefits plans	(1,317.8)	265.0	(428.6)	(573.3)
			(ii) Income taxes relating to items that will not be reclassified to profit or loss	331.7	(66.8)	107.8	144.3
(19.4)	0.9	5.0	b. (i) Items that will be reclassified to profit or loss				
4.8	(0.2)	(1.2)	- Changes in fair value of cash flow hedges	(16.1)	(5.6)	3.4	(0.5)
			(ii) Income taxes relating to items that will be reclassified to profit or loss	4.0	1.2	(0.8)	0.1
(1,009.9)	0.7	248.0	Total Other Comprehensive Income (a+b)	(998.2)	193.8	(318.2)	(429.4)
5,870.2	8,995.6	6,804.1	K Total Comprehensive Income (I+J)	22,342.8	22,814.1	29,668.5	38,899.0
964.2	964.2	964.2	L Paid-up equity share capital (Face value – ₹1 Per share) *	964.2	964.2	964.2	964.2
43,940.7	38,070.5	29,963.3	M Other equity	43,940.7	29,963.3	29,963.3	32,444.7
7.14	9.33	6.80	N Earnings Per Share (EPS) (not annualized for quarters)				
			Basic / Diluted EPS (₹)	24.21	23.46	31.10	40.79
9,690.5	10,671.8	10,023.3	Additional information:				
			Profit from operations [C - A(ii) + B(v) + B(x)]	30,563.8	30,897.4	40,977.8	53,417.9

* Effective from 5th January 2024, 1 (one) equity share having face value of ₹10.00 (Rupees Ten only) each, was sub-divided into 10 (ten) equity shares having face value of ₹1.00 (Rupee One only) each.

Notes:

1. Financial results have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Ind-AS and Schedule III (Division II) to the Companies Act, 2013.
2. The Company has made an investment for 49% stake in Dr. Reddy's and Nestlé Health Science Limited for development of nutraceutical business (refer Note 7 below). Pursuant to this, the investee entity has become an associate of the Company with effect from 24th July 2024. In compliance with section 129(3) of Companies Act, 2013 the financial results of the Company have been presented on standalone as well as consolidated basis.
3. For better understanding of the financial performance, the Company has chosen to present profit from operations as an additional information in the consolidated statement of profit and loss. Profit from operations is derived from profit before exceptional items & tax less other income and adding back finance costs (including interest cost on employee benefits plans) and corporate social responsibility expense.
4. Provision for contingencies are mainly for matters related to litigations/related disputes and other uncertainties requiring management judgement. Provision for contingencies/contingent liabilities are recognised/disclosed after a careful evaluation of the facts and legal aspects of the matters involved, in line with Ind AS 37 Provisions, Contingent Liabilities and Contingent Assets and Ind AS 12 Income Taxes.
5. The Board of Directors on 31st January 2025 have declared second interim dividend for the current financial year 2024-25 of ₹ 14.25 per equity share (Face value ₹ 1/- per equity share) amounting to ₹ 13,739.2 million, which will be paid on and from 27th February 2025. This is in addition to the first interim dividend of ₹ 2.75 per equity share paid on 6th August 2024.
6. Based on the guiding principles given in Ind AS 108 Operating Segments, the Company's business activity falls within a single operating segment, namely Food. Accordingly, no separate segment information has been provided.
7. Exceptional items in the nine months ended 31st December 2024 comprise of gain on slump sale of the businesses mentioned below:
 - a) Nutraceutical Business ("NHSc") to Dr. Reddy's and Nestlé Health Science Limited.
 - b) Nestlé Business Services ('NBS') Division to Nestlé Business Services India Private Limited (Formerly known as Purina PetCare India Private Limited).

THE ABOVE RESULTS AND THIS RELEASE HAVE BEEN REVIEWED BY THE AUDIT COMMITTEE OF THE BOARD AT THEIR MEETING HELD ON 30th JANUARY 2025 AND APPROVED BY THE BOARD OF DIRECTORS AT THEIR MEETING HELD ON 31st JANUARY 2025.

For and on behalf of the Board

SURESH
NARAYANAN

Digitally signed by SURESH
NARAYANAN
Date: 2025.01.31 11:41:05
+05'30'

**Suresh Narayanan
Chairman and Managing Director**

**Date: 31st January 2025
Place: Gurugram**

Head Office: Nestlé House, Jacaranda Marg, M Block, DLF City Phase – II, Gurugram 122 002 (Haryana)
Registered Office: 100 / 101, World Trade Centre, Barakhamba Lane, New Delhi – 110 001
Corporate Identity Number: L15202DL1959PLC003786
Email ID: investor@in.nestle.com, Website: www.nestle.in
Phone: 011-23418891

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Nestle India Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Nestle India Limited (the "Holding Company") and its associate (the Holding Company and its associate together referred to as "the Group") for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of following entities:

Holding Company

- a) Nestle India Limited

Associate

- a) Dr. Reddy's and Nestle Health Science Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. Batliboi & Co. LLP

Chartered Accountants

ICAI Firm registration number: 301003E/E300005

**Pankaj
Chadha**Digitally signed by Pankaj Chadha
DN: cn=Pankaj Chadha, c=IN,
o=Personal,
email=pankaj.chadha@srb.in
Date: 2025.01.31 11:47:50
+05'30'

per Pankaj Chadha

Partner

Membership No.:091813

UDIN: 25091813BMORCS9152

Place: Gurugram

Date: January 31, 2025

PART B - Statement on deviation or variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc. – **Not Applicable**

PART C - Disclosure of outstanding default on loans and debt securities – **Not Applicable, No Default**

PART D - Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – **Not Applicable**

PART E - Statement on impact of audit qualifications (for audit report with modified opinion) submitted along with annual audited financial results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - **Not Applicable**

===